Immugenia Inc. Information

Immugenia Inc. is a preclinical stage immuno-oncology company developing the next generation CAR therapy to treat and prevent relapses in hematological and solid tumors. This is achieved by engineering hematopoietic stem cells using proprietary specific promoters (SPICA) to express CAR in select immune cells leveraging the synergistic activity of T and NK cells. This provides patients with a one-and-done treatment to fight hard-to-treat cancers and prevent relapses.